Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920878940> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2920878940 abstract "355 Background: More than half of patients (pts) with advanced urothelial cell carcinoma (UCC) are ineligible for cisplatin because of renal dysfunction or poor performance status. We investigated the activity and safety of first-line gemcitabine-oxaliplatin (GemOx) compared with gemcitabine-carboplatin (GCb) in cisplatin-ineligible pts with advanced UCC. Methods: Treatment naïve, cisplatin-ineligible pts with advanced UCC were randomly assigned to GemOx (gemcitabine 1000 mg/m2, oxliplatin 100 mg/m2 on D1 Q2W) or GCb (gemcitabine 1000 mg/m2 on D1 and 8, carboplatin AUC 4.5 on D1 Q3W) stratified by ECOG performance status (PS) and visceral metastases. The primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results: Between May 2013 and Mar 2017, 80 pts were enrolled and 79 pts received at least one dose of chemotherapy (39 pts in GCb; 40 pts in GemOx). Median age was 73 years (47-86) and ECOG PS was 2 in 42% of pts and 60% had visceral metastases. Median GFR was 45 ml/min (range 22-108) in GCb and 47 ml/min (range 15-73) in GemOx arm. With median follow-up duration of 37.8 months, all pts were off study treatments. RR were 48.7% and 55.0% in GCb and GemOx, respectively (p = 0.742). Median PFS and OS in GCb and GemOx arm were 5.5 months (95% CI, 4.8-6.2) vs. 4.4 months (95% CI, 2.7-6.1) [HR GemOx/GCb 0.92; p = 0.756] and 9.1 months (95% CI, 5.2-13.0) vs. 11.0 months (95% CI, 6.9-15.0) [HR 0.72; p = 0.194], respectively. The median cycle was 6 (1-10) in GCb and 7 (1-12) in GemOx. Grade 3 leukopenia, neutropenia and fatigue were more common in GCb arm (25.6% vs. 2.5%, p = 0.003; 33.3% vs. 10.0%, p = 0.014; 15.4% vs. 0%, p = 0.012). Dose delay and reduction in GCb and GemOx group were needed in 46.2%, 50.0% and 53.8%, 32.5%, respectively. Salvage chemotherapy after study treatment was offered in 54.3% and 55.9% of patients who experienced PD in GCb and GemOx arm. Conclusions: GemOx has showed comparable efficacy with GCb and favorable hematologic toxicity profile. GemOx may be used as a new option for patients who are not suitable for cisplatin-containing chemotherapy. Clinical trial information: NCT01487915." @default.
- W2920878940 created "2019-03-22" @default.
- W2920878940 creator A5007931207 @default.
- W2920878940 creator A5015598872 @default.
- W2920878940 creator A5021046796 @default.
- W2920878940 creator A5022408548 @default.
- W2920878940 creator A5024696454 @default.
- W2920878940 creator A5035331177 @default.
- W2920878940 creator A5048145361 @default.
- W2920878940 creator A5060830854 @default.
- W2920878940 creator A5063838757 @default.
- W2920878940 creator A5070418550 @default.
- W2920878940 creator A5077382108 @default.
- W2920878940 creator A5079540101 @default.
- W2920878940 creator A5084818663 @default.
- W2920878940 date "2019-03-01" @default.
- W2920878940 modified "2023-09-27" @default.
- W2920878940 title "Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study)." @default.
- W2920878940 doi "https://doi.org/10.1200/jco.2019.37.7_suppl.355" @default.
- W2920878940 hasPublicationYear "2019" @default.
- W2920878940 type Work @default.
- W2920878940 sameAs 2920878940 @default.
- W2920878940 citedByCount "0" @default.
- W2920878940 crossrefType "journal-article" @default.
- W2920878940 hasAuthorship W2920878940A5007931207 @default.
- W2920878940 hasAuthorship W2920878940A5015598872 @default.
- W2920878940 hasAuthorship W2920878940A5021046796 @default.
- W2920878940 hasAuthorship W2920878940A5022408548 @default.
- W2920878940 hasAuthorship W2920878940A5024696454 @default.
- W2920878940 hasAuthorship W2920878940A5035331177 @default.
- W2920878940 hasAuthorship W2920878940A5048145361 @default.
- W2920878940 hasAuthorship W2920878940A5060830854 @default.
- W2920878940 hasAuthorship W2920878940A5063838757 @default.
- W2920878940 hasAuthorship W2920878940A5070418550 @default.
- W2920878940 hasAuthorship W2920878940A5077382108 @default.
- W2920878940 hasAuthorship W2920878940A5079540101 @default.
- W2920878940 hasAuthorship W2920878940A5084818663 @default.
- W2920878940 hasConcept C121608353 @default.
- W2920878940 hasConcept C126322002 @default.
- W2920878940 hasConcept C126894567 @default.
- W2920878940 hasConcept C143998085 @default.
- W2920878940 hasConcept C2776694085 @default.
- W2920878940 hasConcept C2778239845 @default.
- W2920878940 hasConcept C2780258809 @default.
- W2920878940 hasConcept C2780352672 @default.
- W2920878940 hasConcept C2780962732 @default.
- W2920878940 hasConcept C2781451048 @default.
- W2920878940 hasConcept C3019882237 @default.
- W2920878940 hasConcept C31760486 @default.
- W2920878940 hasConcept C526805850 @default.
- W2920878940 hasConcept C71924100 @default.
- W2920878940 hasConceptScore W2920878940C121608353 @default.
- W2920878940 hasConceptScore W2920878940C126322002 @default.
- W2920878940 hasConceptScore W2920878940C126894567 @default.
- W2920878940 hasConceptScore W2920878940C143998085 @default.
- W2920878940 hasConceptScore W2920878940C2776694085 @default.
- W2920878940 hasConceptScore W2920878940C2778239845 @default.
- W2920878940 hasConceptScore W2920878940C2780258809 @default.
- W2920878940 hasConceptScore W2920878940C2780352672 @default.
- W2920878940 hasConceptScore W2920878940C2780962732 @default.
- W2920878940 hasConceptScore W2920878940C2781451048 @default.
- W2920878940 hasConceptScore W2920878940C3019882237 @default.
- W2920878940 hasConceptScore W2920878940C31760486 @default.
- W2920878940 hasConceptScore W2920878940C526805850 @default.
- W2920878940 hasConceptScore W2920878940C71924100 @default.
- W2920878940 hasLocation W29208789401 @default.
- W2920878940 hasOpenAccess W2920878940 @default.
- W2920878940 hasPrimaryLocation W29208789401 @default.
- W2920878940 isParatext "false" @default.
- W2920878940 isRetracted "false" @default.
- W2920878940 magId "2920878940" @default.
- W2920878940 workType "article" @default.